Over the previous year, there has also been elevated attention to broad-population medicine similar to GLP-1s . The number of patients meeting clinical eligibility standards for these medication is among the largest of any new drug class prior to now 20 to 30 years. The increased concentrate on these drugs has amplified conversations about care and coverage choices, including Health News issues around demonstrated adherence to therapy, utilization management measures, and prescriber access factors . As we look forward, patient affordability, cost containment, and predictability of spending will probably stay key themes within the sector. These adjustments, coupled with elevated…